Imexpharm (STC:IMP) Moat Score: 0/10 (As of Jun. 28, 2026)


STC:IMP Imexpharm Corp STC:IMP
98 GF Score
Price ₫42,050.00
GF Value ₫51,706.57
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Imexpharm Moat Score?

Imexpharm has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Imexpharm has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Imexpharm might have No Moat - No discernible moat.

Imexpharm  (STC:IMP) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Imexpharm Moat Score Related Terms

STC:IMP
98GF Score
Imexpharm Corp STC:IMP
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Imexpharm (STC:IMP) Overvalued in 2026?

Based on GuruFocus' analysis, Imexpharm stock appears to be undervalued. The current stock price of ₫42,050.00 is trading 18.7% below its estimated GF Value™ of ₫51,706.57. GuruFocus considers Imexpharm to be Modestly Undervalued.

Key valuation signals for STC:IMP:

  • Moat Score: 0
  • GF Value™: ₫51,706.57 vs. price of ₫42,050.00 (18.7% below fair value)
  • GF Score™: 98/100 with 2 warning signs

No single metric tells the full story. See the STC:IMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Imexpharm Business Description

Address 4 Road 30/04 Street Ward 1, Cao Lanh City, Dongthap, VNM
Imexpharm Corp is engaged in the manufacture, import, export, and trade of pharmaceuticals and medicinal chemical products. The company's products include oral and injective antibiotic, digestion, central nervous system, cardiovascular, diabetes, musculoskeletal system, respiratory system, analgesic-anti-inflammatory, anti-allergy, ophthalmology, external drugs, and anti-parasitic, as well as vitamins and minerals.
98GF Score

Get the complete analysis for STC:IMP

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₫42,050.00
Price
₫51,706.57
GF Value